Pharmaceutical companies relying on blockbuster drugs to fuel their profits could suffer more damage from generic competition in the next several years than Wall Street expects, a Bernstein Research analyst says.
In a report released Tuesday, Bernstein analyst Dr. Tim Anderson said AstraZeneca, Eli Lilly & Co. and Bristol-Myers Squibb Co. are among drug developers most vulnerable to the loss of key patents in the next five years.
The pharmaceutical industry in large part is facing a "patent cliff," or the loss of key patents on revenue-driving drugs, opening the door for competition from cheaper generics.
Key drugs, such as Bristol-Myers' blood-thinner Plavix, make up a large percent of their respective companies' profit margins, Anderson said.
Companies rarely disclose the profitability of a specific drug, making it difficult to model the full impact of a sales decline to a company's bottom-line, he added.
"Our work yields a very important finding: just how much a small collection of major brands can fund the operations of the rest of the company, and how they enable things like the heavy investment in research and development, and other expensive endeavors," he said. "What, then, will happen as these sources of funding dry up?"
He said roughly 30 of the 52 drugs modeled have pretax margins that are 70 percent or higher. Many of the products are above 80 percent and a few products approach 90 percent.
Sales of Plavix are expected to fall off after patents start to expire in 2011. Anderson expects the drug's contribution to pre-tax income to dive to $156 million in 2015 from $2.93 billion in 2009.
Eli Lilly's anti-psychotic medication Zyprexa is estimated to contribute $518 million to pretax income in 2015, down from $3.81 billion in 2009.
Pfizer Inc. and Merck & Co. face similar declines with the cholesterol drug Lipitor and allergy drug Singulair, respectively. But, those companies have helped offset the overall impact to profit by pursuing large acquisitions, he said.
Those deals both added to the existing portfolio of products and gave a boost to research and development potential.
Other potential solutions for the industry include investing in new drugs, while cutting costs in sales forces and infrastructure, he said.
© Copyright 2013 The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.